Tolcapone - SOM Biotech

Drug Profile

Tolcapone - SOM Biotech

Alternative Names: Amyloid inhibitor - SOM Biotech; SOM 0226

Latest Information Update: 09 Sep 2016

Price : $50

At a glance

  • Originator SOM Biotech
  • Developer SOM Biotech; Vall d-Hebron Research Institute
  • Class Antiparkinsonians; Benzophenones; Nitrophenols; Small molecules
  • Mechanism of Action Amyloid inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloid polyneuropathy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Amyloid polyneuropathy

Highest Development Phases

  • Phase II Amyloid polyneuropathy

Most Recent Events

  • 02 May 2016 SOM Biotech's Tolcapone is available for licensing as of 08 Sep 2016. http://www.sombiotech.com/partnering
  • 02 May 2016 SOM Biotech has patent protection for repurposed tolcapone in Countries worldwide
  • 24 Jul 2014 SOM 0226 is available for licensing as of 24 Jul 2014. http://www.sombiotech.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top